The trial will evaluate the impact of BPL-003 plus psychological support in patients with treatment resistant depression. Credit: Andrew Neel on Unsplash.

Beckley Psytech has commenced a Phase IIa clinical trial of synthetic 5-Methoxy-N, N-Dimethyltryptamine’s (5-MeO-DMT) intranasal formulation, BPL-003, for treatment resistant depression (TRD).

The company plans to enrol the first subject in the trial in January next year. 

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial will be carried out at King’s College Hospital and Hammersmith Medicines Research.

It will evaluate the impact of one dose of BPL-003 plus psychological support in patients with moderate to severe symptoms of TRD. 

This trial will have such patients who are not receiving any antidepressants parallelly and be followed up for 12 weeks after the dosing.

See Also:

Safety, pharmacokinetic and efficacy evaluations will be carried out at various time points throughout the trial. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Additionally, the company plans to launch a second exploratory trial of the compound early next year. 

This study is expected to evaluate the impact of one dose of BPL-003 plus abstinence-oriented cognitive behavioural support in individuals with alcohol use disorder.

Beckley Psytech CEO Cosmo Feilding Mellen said: “Conditions like treatment resistant depression have a devastating effect on people around the world, but they are sadly underserved when it comes to treatment opportunities. 

“We are proud to be conducting rigorous scientific investigations into the therapeutic potential of novel, short-acting psychedelic compounds like BPL-003 to help people in urgent need and we are looking forward to dosing the first patient in the coming weeks.”

In November this year, the company concluded the Phase I trial of BPL-003 in 44 psychedelic-naïve subjects.

According to the trial findings, the treatment had a dose-proportional pharmacokinetic (PK) profile and favourable tolerability without any serious adverse events.